OmniAb, Inc. Common Stock (OABI) stock fundamentals

Read this company snapshot

Company overview

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Daily valuation snapshot

Read OABI's valuation metrics

1. Company size

   OmniAb, Inc. Common Stock's recorded market capitalization is $696,420,006.42. It measures the market value of the company's equity, rather than its revenue or cash balance.

2. Price relative to earnings

   P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.

3. Price relative to book equity

   OABI's recorded price-to-book ratio is 2.68. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.

Research OmniAb, Inc. Common Stock with Aurora

Use the snapshot above to ask a specific question about OABI. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.

Continue the research

Follow OABI's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.